Formycon AG (HAM:FYB) Short Interest


HAM:FYB Formycon AG HAM:FYB
65 GF Score
Price €18.86
GF Value €35.48
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Formycon AG Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

HAM:FYB vs VRTX, REGN, ALNY: Short Interest Comparison

For the Biotechnology subindustry, Formycon AG's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Formycon AG Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Formycon AG's Short Interest distribution charts can be found below:

* The bar in red indicates where Formycon AG's Short Interest falls into.


HAM:FYB
65GF Score
Formycon AG HAM:FYB
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Formycon AG (HAM:FYB) Overvalued in 2026?

Based on GuruFocus' analysis, Formycon AG stock appears to be undervalued. The current stock price of €18.86 is trading 46.8% below its estimated GF Value™ of €35.48. GuruFocus considers Formycon AG to be Possible Value Trap.

Key valuation signals for HAM:FYB:

  • Short Interest:
  • GF Value™: €35.48 vs. price of €18.86 (46.8% below fair value)
  • GF Score™: 65/100 with 5 warning signs

No single metric tells the full story. See the HAM:FYB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Formycon AG Business Description

Address Fraunhoferstrasse 15, Martinsried, Planegg, BY, DEU, 82152
Formycon AG is an independent developer of high-quality biosimilars, which are follow-on products to biopharmaceutical drugs. The Company focuses on expanding and further developing its scalable biosimilar platform, which includes approved and pipeline products across ophthalmology, immunology, and immuno-oncology. Its key products include FYB201 (ranibizumab), FYB202 (ustekinumab), FYB203 (aflibercept), FYB206 (pembrolizumab), and FYB208 (dupilumab), along with additional biosimilar candidates in various stages of development. The Company generates maximum revenue from Switzerland.
65GF Score

Get the complete analysis for HAM:FYB

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€18.86
Price
€35.48
GF Value